STATCenter·
STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program
The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout
Read at STAT →
Health · 1 sources covering this
STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program
The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/6f2a000e56401c28c830167e79334f334cb86f4e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program"></iframe>
